GPC3 and hepatocellular carcinoma: Interestingly, the combination of anti-PD-L1 CAR (B2)-T cells and anti-GPC3 CAR-T cells synergistically demonstrated better efficacy than single-antigen-targeted CAR-T cells in the HCC xenograft mouse model, highlighting the feasibility and efficacy of shark VNAR-based CAR-T cells targeting PD-L1 in solid tumors.